Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF)

Frontiers in Endocrinology

Volumn 3, Issue DEC, 2012, Pages

  Fung, Chunkit ^a   Vaughn, David J ^b   Mitra, Nandita ^c   Ciosek, Stephanie L ^b   Vardhanabhuti, Saran ^d   Nathanson, Katherine L ^b   Kanetsky, Peter A ^c  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

Author keywords

Arvcf; Comt; Gstp1; Neuropathy; Ototoxicity; Refractory disease; Testicular germ cell tumor; Tpmt

Indexed keywords

EID: 84874414652     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2012.00163     Document Type: Article

References (35)

1. Aass, N., Kaasa, S., Lund, E., Kaalhus, O., Heier, M. S., and Fossa, S. D. (1990). Long-term somatic side-effects and morbidity in testicular cancer patients. Br. J. Cancer 61, 151-155.
2. Benjamini, Y., and Hochberg,Y. (1995). Controlling the false discovery rate -a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289-300.
3. Bissett, D., Kunkeler, L., Zwanenburg, L., Paul, J., Gray, C., Swan, I. R., et al. (1990). Long-term sequelae of treatment for testicular germ cell tumours. Br. J. Cancer 62, 655-659.
4. Bokemeyer, C., Berger, C. C., Hartmann, J. T., Kollmannsberger, C., Schmoll, H. J., Kuczyk, M. A., et al. (1998). Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br. J. Cancer 77, 1355-1362.
5. Bokemeyer, C., Berger, C. C., Kuczyk, M. A., and Schmoll, H. J. (1996). Evaluation of long-term tox-icity after chemotherapy for testicular cancer. J. Clin. Oncol. 14, 2923-2932.
6. Boyer, M., Raghavan, D., Harris, P. J., Lietch, J., Bleasel, A., Walsh, J. C., et al. (1990). Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J. Clin. Oncol. 8, 21-26.
7. Brydoy, M., Oldenburg, J., Klepp, O., Bremnes, R. M., Wist, E. A., Wentzel-Larsen, T., et al. (2009). Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J.Natl. Cancer Inst. 101, 1682-1695.
8. Coate, L., Cuffe, S., Horgan, A., Hung, R. J., Christiani, D., and Liu, G. (2010). Germline genetic variation, cancer outcome, and phar-macogenetics. J. Clin. Oncol. 28, 4029-4037.
9. de Haas, E. C., Zwart, N., Meijer, C., Nuver, J., Boezen, H. M., Suurmeijer, A. J., et al. (2008). Variation in bleomycin hydrolase gene is associated with reduced survival after chemotherapy for testicular germ cell cancer. J. Clin. Oncol.26, 1817-1823.
10. de Haas, E. C., Zwart, N., Meijer, C., Suurmeijer, A. J., Meijer, K., Guchelaar, H. J., et al. (2010). Association of PAI-1 gene polymorphism with survival and chemotherapy-related vascular toxicity in testicular cancer. Cancer 116,5628-5636.
11. Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., and Greene, D. A. (1994). A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17, 1281-1289.
12. Ferlin, A., Ganz, F., Pengo, M., Selice, R., Frigo, A. C., and Foresta, C. (2010). Association of testicular germ cell tumor with polymorphisms in estrogen receptor and steroid metabolism genes. Endocr. Relat Cancer 17, 17-25.
13. Fotsis, T., Zhang, Y., and Pepper, M. S., Adlercreutz, H., Montesano, R., Nawroth, P. P., et al. (1994). The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368, 237-239.
14. Fung, C., and Vaughn, D. J. (2011). Complications associated with chemotherapy in testicular cancer management. Nat. Rev. Urol. 8, 213-222.
15. Garolla, A., Ferlin, A., Vinanzi, C., Roverato, A., Sotti, G., Artibani, W., et al. (2005). Molecular analysis of the androgen receptor gene in testicular cancer. Endocr. Relat. Cancer 12, 645-655.
16. Glendenning, J. L., Barbachano, Y., Norman, A. R., Dearnaley, D. P., Horwich, A., and Huddart, R. A. (2010). Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 116, 2322-2331.
17. Hansen, S. W., Helweg-Larsen, S., and Trojaborg, W. (1989). Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer. J. Clin. Oncol. 7, 1457-1461.
18. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., et al. (2008). Cancer statistics, 2008. CA. CancerJ. Clin. 58, 71-96.
19. Kanetsky, P. A., Mitra, N., Vardhanabhuti, S., Li, M., Vaughn, D. J., Letrero, R., et al. (2009). Common variation in KITLG and at 5q31.3 predisposes to testicular germ cell cancer. Nat. Genet. 41, 811-815.
20. Kanetsky, P. A., Mitra, N., Vardhanabhuti, S., Vaughn, D. J., Li, M., Ciosek, S. L., et al. (2011). A second independent locus within DMRT1 is associated with testicular germ cell tumor susceptibility. Hum. Mol. Genet. 20, 3109-3117.
21. Lin, D. W., FitzGerald, L. M., Fu, R., Kwon, E. M., Zheng, S. L., Kolb, S., et al. (2011). Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol. Biomarkers Prev. 20, 1928-1936.
22. Mannervik, B., Alin, P., Guthenberg, C., Jensson, H., Tahir, M. K., Warholm, M., et al. (1985). Identification of three classes of cytosolic glu-tathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc. Natl. Acad. Sci. U.S.A. 82, 7202-7206.
23. Moghtaderi, A., Bakhshipour, A., and Rashidi, H. (2006). Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clin. Neurol. Neurosurg. 108,477-481.
24. National Cancer Institute. (2011). SEER Cancer Statistics Review, 1975-2008. [Accessed October 12, 2011]. Available online at: http://cancercontrol.cancer.gov/ocs prevalence/prevalence.html#male
25. Ochoa, B., Bobadilla, N., Arrellin, G., and Herrera, L. A. (2009). S-Adenosyl-L-methionine increases serum BUN and creatinine in cisplatin-treated mice. Arch. Med. Res. 40, 54-58.
26. Oldenburg, J., Kraggerud, S. M., Brydoy, M., Cvancarova, M., Lothe, R. A., and Fossa, S. D. (2007). Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and-M1, a retrospective cross sectional study. J. Transl. Med. 5, 70.
27. Oldenburg, J., Kraggerud, S. M., Cvancarova, M., Lothe, R. A., and Fossa, S. D. (2007). Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J. Clin. Oncol. 25, 708-714.
28. Petersen, P. M., and Hansen, S. W. (1999). The course of long-term toxicity in patients treated with cisplatin-based chemotherapy for non-seminomatous germ-cell cancer. Ann. Oncol. 10, 1475-1483.
29. Reintsch, W. E., Mandato, C. A., McCrea, P. D., and Fagotto, F. (2008). Inhibition of cell adhesion by xARVCF indicates a regulatory function at the plasma membrane. Dev.Dyn. 237,2328-2341.
30. Ross, C. J., Katzov-Eckert, H., Dube, M. P., Brooks, B., Rassekh, S. R., Barhdadi, A., et al. (2009). Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet. 41, 1345-1349.
31. Roth, B. J., Greist, A., Kubilis, P. S., Williams, S. D., and Einhorn, L. H. (1988). Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J. Clin. Oncol. 6, 1239-1247.
32. Sinisi, A. A., Pasquali, D., Notaro, A., and Bellastella, A. (2003). Sexual differentiation. J. Endocrinol. Invest. 26, 23-28.
33. von Schlippe, M., Fowler, C. J., and Harland, S. J. (2001). Cisplatin neurotoxicity in the treatment of metastatic germ cell tumour: time course and prognosis. Br. J. Cancer 85, 823-826.
34. Wanderas, E. H., Fossa, S. D., and Tretli, S. (1997). Risk of subsequent non-germ cell cancer after treat ment of germ cell cancer in 2006 Norwegian male patients. Eur. J. Cancer 33, 253-262.
35. Weinshilboum, R. M. (2006). Pharmacogenomics:catechol O-methyltransferase to thiopurine S-methyltransferase. Cell. Mol. Neurobiol. 26,539-561.